Novo Nordisk invests DKK 750 million in new laboratories for diabetes research in Denmark

Novo Nordisk invests DKK 750 million in new laboratories for diabetes research in Denmark

Bagsværd, Denmark, 31 October 2014 - Novo Nordisk today announced an investment of approximately 750 million Danish kroner (around 130 million US dollars) in new laboratories at the company's R&D campus in Måløv, Denmark. Construction has started, and the new laboratory facility is expected to be ready for occupation in early 2016.

The new facility - Diabetes Research House - will accommodate approximately 350 employees. During the construction phase, the project is expected to generate more than 1,000 jobs outside Novo Nordisk.

"The new lab facility will provide an environment for cutting-edge diabetes research within biotechnology and protein chemistry," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "Here our researchers will be working closely together with leading scientists in Denmark and abroad on the discovery and development of new medicines for the treatment of type 1 and type 2 diabetes."

The facility comprises two laboratory wings, a middle building with office space and an auditorium seating 450 people. The facility will have a floorage of 16,500 square metres distributed on three storeys.

Novo Nordisk opened its R&D campus in Måløv in 1991 with about 300 employees. Today the campus accommodates more than 2,300 employees. Globally, about 5,000 employees are involved in research and development activities at Novo Nordisk's R&D units in Denmark, the US and China.

Graphics of Diabetes Research House can be downloaded on under Photos.

Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 40,700 employees in 75 countries, and markets its products in more than 180 countries. 

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.